Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NASDAQ:BLFS NASDAQ:INMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$44.72-0.5%$41.65$10.50▼$46.00$2.39B1.121.38 million shs1.15 million shsBLFSBioLife Solutions$28.30-1.3%$24.18$17.86▼$30.00$1.40B2957,761 shs3.41 million shsINMDInMode$14.74+0.8%$13.93$12.72▼$16.74$840.94M1.94753,637 shs591,778 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen0.00%+0.20%+13.80%+43.45%+327.90%BLFSBioLife Solutions0.00%+10.04%+14.99%+52.58%+33.34%INMDInMode0.00%+9.15%+5.00%+9.07%+3.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$44.72-0.5%$41.65$10.50▼$46.00$2.39B1.121.38 million shs1.15 million shsBLFSBioLife Solutions$28.30-1.3%$24.18$17.86▼$30.00$1.40B2957,761 shs3.41 million shsINMDInMode$14.74+0.8%$13.93$12.72▼$16.74$840.94M1.94753,637 shs591,778 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen0.00%+0.20%+13.80%+43.45%+327.90%BLFSBioLife Solutions0.00%+10.04%+14.99%+52.58%+33.34%INMDInMode0.00%+9.15%+5.00%+9.07%+3.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 2.73Moderate Buy$46.503.98% UpsideBLFSBioLife Solutions 2.40Hold$32.0013.07% UpsideINMDInMode 2.00Hold$16.008.55% UpsideCurrent Analyst Ratings BreakdownLatest INMD, BLFS, and AXGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026AXGNAxoGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/29/2026AXGNAxoGen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/12/2026BLFSBioLife Solutions Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2026INMDInMode BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$21.00 ➝ $19.005/7/2026INMDInMode Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$17.00 ➝ $14.004/29/2026AXGNAxoGen Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$48.004/29/2026AXGNAxoGen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $50.004/29/2026AXGNAxoGen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$39.00 ➝ $50.004/29/2026AXGNAxoGen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/29/2026AXGNAxoGen Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$40.00 ➝ $48.004/29/2026AXGNAxoGen Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$42.00 ➝ $50.00(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$238.11M9.99N/AN/A$2.79 per share16.03BLFSBioLife Solutions$96.21M14.37$0.23 per share125.21$7.72 per share3.67INMDInMode$370.49M2.29$1.50 per share9.81$10.78 per share1.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$15.70M-$0.64N/A165.63N/A-13.21%-9.63%-6.26%8/4/2026 (Estimated)BLFSBioLife Solutions-$4.59M-$0.08N/A141.50N/A-2.80%1.81%1.65%8/6/2026 (Estimated)INMDInMode$93.83M$1.3610.84N/AN/A23.27%13.47%11.95%7/23/2026 (Estimated)Latest INMD, BLFS, and AXGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/23/2026Q2 2026INMDInMode$0.3314N/AN/AN/A$92.64 millionN/A5/7/2026Q1 2026BLFSBioLife Solutions$0.01$0.04+$0.03$0.02$25.66 million$27.50 million5/6/2026Q1 2026INMDInMode$0.2978$0.25-$0.0478$0.18$79.84 million$82.02 million4/28/2026Q1 2026AXGNAxoGen$0.12$0.07-$0.05-$0.38$57.85 million$61.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ABLFSBioLife SolutionsN/AN/AN/AN/AN/AINMDInModeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.087.105.33BLFSBioLife SolutionsN/A7.305.50INMDInModeN/A8.807.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%BLFSBioLife Solutions93.24%INMDInMode68.04%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.44%BLFSBioLife Solutions2.20%INMDInMode6.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45053.18 million51.88 millionOptionableBLFSBioLife Solutions44048.86 million47.78 millionOptionableINMDInMode48057.48 million53.50 millionOptionableBLFS, INMD, and AXGN HeadlinesRecent News About These CompaniesInMode Ltd. (NASDAQ:INMD) Given Consensus Recommendation of "Hold" by BrokeragesJune 27 at 2:48 AM | americanbankingnews.comDOMA PERPETUAL CAPITAL MANAGEMENT STRONGLY OPPOSES INMODE BUYOUT AS PROPOSED; PLANS TO VOTE AGAINST DEALJune 26 at 8:25 AM | prnewswire.comInMode: It's Time To Exit The Theater (Rating Downgrade)June 25, 2026 | seekingalpha.comINMD stock heads for best day in nearly six months – how does the latest takeover proposal compare to Steel Partners’ offer?June 24, 2026 | msn.comMedical aesthetics play flies on unsolicited takeover bid; why it makes senseJune 24, 2026 | msn.comInMode Forms Special Committee to Review CEO-Backed $16.20-Per-Share Takeover ProposalJune 24, 2026 | tipranks.comInMode Confirms Receipt of Unsolicited ProposalJune 24, 2026 | prnewswire.comInMode Sets July 30, 2026 Annual General Meeting and Outlines Director, Auditor and Compensation VotesJune 18, 2026 | tipranks.comInMode Ltd. (INMD) Presents at Jefferies Global Healthcare Conference 2026 - SlideshowJune 4, 2026 | seekingalpha.comInMode: My Pick For A Major Turnaround In 2026 And 2027May 28, 2026 | seekingalpha.comInmode Ltd (INMD) Reports Solid Numbers in a Soft MarketMay 27, 2026 | insidermonkey.comAnalysts Conflicted on These Healthcare Names: InMode (INMD), Achieve Life Sciences (ACHV) and BioNTech SE (BNTX)May 23, 2026 | theglobeandmail.comInMode LTD: InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial OfficerMay 20, 2026 | finanznachrichten.deInMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial OfficerMay 20, 2026 | prnewswire.comInMode to Present at Upcoming Investor Conferences and EventsMay 13, 2026 | prnewswire.comInmode Earnings Call: Growth Intact, Margins Under StrainMay 10, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Bio-Techne (TECH) and InMode (INMD)May 8, 2026 | theglobeandmail.comInMode (INMD) Q1 2026 Earnings Call TranscriptMay 7, 2026 | finance.yahoo.comInMode Ltd. (INMD) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comInMode LTD.: InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year IncreaseMay 6, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLFS, INMD, and AXGN Company DescriptionsAxoGen NASDAQ:AXGN$44.72 -0.21 (-0.47%) Closing price 04:00 PM EasternExtended Trading$44.72 0.00 (0.00%) As of 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.BioLife Solutions NASDAQ:BLFS$28.30 -0.37 (-1.29%) Closing price 04:00 PM EasternExtended Trading$28.26 -0.04 (-0.12%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.InMode NASDAQ:INMD$14.74 +0.11 (+0.75%) Closing price 04:00 PM EasternExtended Trading$14.74 -0.01 (-0.03%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
